BEIJING, May 19, 2026 (GLOBE NEWSWIRE) — KE Holdings Inc. (“Beike” or the “Company”) (NYSE: BEKE; HKEX: 2423), a leading integrated online and offline platform for housing transactions and services, today announced its unaudited financial results for the first quarter ended March 31, 2026. Business and Financial Highlights for the First Quarter 2026Gross transaction value (GTV)1 was RMB711.7 billion (US$103.2 billion), a decrease of 15.6% year-over-year. GTV of existing home transactions was RMB534.4 billion (US$77.5 billion), a decrease of 7.9% year-over-year. GTV of new home transactions was RMB145.9 billion (US$21.2 billion), a decrease of 37.2% year-over-year. Net revenues were RMB18.9 billion (US$2.7 billion), a decrease of 19.0% year-over-year. Net income was RMB1,255 million (US$182 million), an increase of 46.7% year-over-year....

CARLSBAD, Calif., May 19, 2026 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $4.3 million, or $0.72 per diluted share, on net sales of $35.5 million for the third quarter of fiscal year 2026 compared to a net loss of $2.2 million, or $0.37 per diluted share, in the third quarter of the prior fiscal year. Net sales during the three months ended March 31, 2026, increased $6.7 million, or 23%, to $35.5 million as compared to $28.8 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 25% to $33.8 million, primarily due to increased orders from one of our largest customers and shipments to new...

Report on first quarter of 2026for ROCKWOOL A/SRelease no. 16 – 2026to Nasdaq Copenhagen 19 May 2026 Resilient first quarter revenue growth amid global uncertainty Highlights1Demonstrating resilient growth despite continued geopolitical turbulence and unusual weather conditions in Europe and North America, revenue in Q1 2026 reached 906 MEUR, an increase of two percent measured in local currencies and flat in reported figures compared to last year. We expect that energy and raw material cost levels will remain elevated. To protect margins, we have implemented additional price increases in the range of 6-8 percent, with main impact from the middle of the year. EBITDA in Q1 2026 reached 187 MEUR, with a 20.7 percent EBITDA margin, a good result although down 2.1 percentage points compared to the record high quarter last year. The production...

Quarterly net revenues were RMB680.6 million (US$98.7 million)1 Quarterly lidar shipments were 471,723 units Quarterly net income was RMB18.3 million (US$2.7 million) SHANGHAI, China, May 19, 2026 (GLOBE NEWSWIRE) — Hesai Group (“Hesai” or the “Company”) (NASDAQ: HSAI; HKEX: 2525), a global tech company and a leader in 3D perception, today announced its unaudited financial results for the three months ended March 31, 2026. Management Remarks “We are incredibly honored and excited to announce that Hesai serves as strategic lidar partner and confirmed supplier for Mercedes-Benz models enabling L3 autonomy. Meanwhile, the first quarter of 2026 marked a transformative chapter for Hesai as we began our strategic evolution from ‘Spatial Perception’ to ‘Spatial Intelligence.’ We are no longer just a global leader in lidar; we are building...

LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 (“FY25”). FY25 Highlights Research & Development (R&D) HighlightsIncreased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programsGen Two (AVA6103):First patient received treatment in FOCUS-01, a multicenter, open-label Phase 1 clinical trial of AVA6103 (FAP-Exd, pre|CISION®-enabled exatecan) – March 2026. The FOCUS-01...